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Abstract
Background: Hepatitis C virus (HCV) mono-infection and HCV/HIV (human immunodeficiency virus) co-infection are
growing problems in injection drug users (IDU). Their prevalence and genotypic patterns vary with geographic locations.
Access to harm reduction measures is opening up opportunities for improving the HIV/HCV profiling of IDU in China, where
IDUs account for a significant proportion of the two infections especially in the southern part of the country.
Methodology/Principal Findings: A cross sectional study was conducted. Through the Liuzhou Methadone Clinic, a total of
117 injection drug users (IDUs) were recruited from Guangxi, Southern China. A majority of the IDUs (96%) were HCV
antibody positive, of which 21% were HIV infected. Unlike HCV monoinfection, there was spatial heterogeneity in the
distribution of HIV/HCV coinfection, the latter also characterized by a higher prevalence of needle-sharing. Phylogenetic
analysis revealed that genotype 6a was predominant in the study population. There were shorter genetic distances among
the 6a sequences compared to the other HCV subtypes-1a, 3a, and 3b.
Conclusion/Significance: The results suggested that HIV and HCV were introduced at around the same time to the IDU
populations in Southern China, followed by their differential spread as determined by the biologic characteristics of the
virus and the intensity of behavioural risk. This pattern is different from that in other South East Asian countries where HCV
infections have probably predated HIV.
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Introduction
Hepatitis C Virus (HCV) infection is a worldwide health
problem characterized by the lack of an effective vaccine, need for
expensive treatment, chronicity of morbidity and associated
mortality [1]. HCV shares the same transmission routes with
human immunodeficiency virus (HIV). It is however more
efficiently transmitted through exposure to contaminated blood,
as well as needle-sharing in injection drug users (IDUs).
Worldwide, more than 170 million people are infected by HCV,
more than 4 times the number of people living with HIV. The
prevalence of HIV/HCV coinfection in IDUs is also high, ranging
from 50% to less than 10% in different regions [2,3]. HCV
infection has become one of the most important causes of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma in China.
Currently, more than 70% of IDUs in Southern China are
infected with HCV [4]. Most have been reported in Yunnan,
Guangxi, and Guangdong province [4,5].
HCV is a spherical, enveloped virus with a linear positive sense
RNA genome of approximately 9.6 kb in length [6]. One of the
most important features of HCV is its high degree of genetic
variability. Variations of the HCV genome have led to its
classification into six major genotypes and a large number of
subtypes. The different genotypes display up to 70% sequence
similarity, whereas subtypes vary by more than 20% [7]. The open
reading frame (ORF) encodes the structural proteins core (C),
envelope (E1, E2), and the non-structural proteins (NS2, NS3,
NS4a NS4b, NS5a and NS5b) [6]. Region E2 displays most
sequence diversity, whereas 5_UTR and CORE sequences are
more conserved [8,9]. Response to interferon (IFN)-based
therapies in patients infected with HCV genotype 4 and 1 is
much lower than that for genotypes 2 and 3 [10]. Clinically,
genotyping of HCV is therefore important for predicting
treatment responses and for determining the duration of antiviral
therapy. HCV genotyping is also of public health importance as it
can be useful for investigating outbreaks and for understanding the
epidemiology of the infection [5,11]. To date, genotypes 1, 2 and 3
have a worldwide distribution while the others are more localized.
Genotype 4, for example, is mostly found in Middle East and
North Africa; while 5 is common in South Africa and 6 in South
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1, 2, and 3 because they are pandemic, but relatively little is
known about the epidemiology of genotype 6 which is circulating
in South East Asian countries and neighboring China.
Southern China borders the South East Asian countries of
Myanmar, Laos, and Vietnam, the latter forming the Golden
Triangle, one main producer of heroin in the region. Guangxi is
the neighbor of Yunnan province, which is becoming an
important focal point for trafficking drugs from countries of South
East Asia to inner China [4]. In anticipation of the rising threat of
HIV/HCV infections, methadone treatment programme was
initiated in China [15]. Methadone clinics provide access of harm
reduction measures to high risk populations. We undertook to
examine the molecular epidemiology of HIV and HCV infections
through these new outlets.
Materials and Methods
Study participants
Drug users were recruited from the Liuzhou Methadone Clinic
in Guangxi, Southern China, from August 2006 to October 2006.
The clinic is run by Liuzhou Center for Disease Control and
Prevention (Liuzhou CDC). Written consent was obtained and the
participants were interviewed by trained research staff to
determine their demographics, drug addiction patterns, and sexual
risk behaviours. Blood samples were centrifuged, aliquoted and
stored at 270uC before testing for HIV and HCV antibody, and
for HCV genotyping. Patients were informed that the tests
requested in the study were designed for epidemiological research.
As regards clinical testing, all patients at the methadone clinics had
access to HIV tests and related counseling by professional staff.
Those tested positive were referred to the specialist clinic run by
the same CDC, where standard antiretroviral therapy was
prescribed in accordance with national treatment guidelines.
HCV counseling and treatment were however not available as a
standard practice, and this study served to determine the
dimension and characteristics of the condition. In our study
protocol, communication of laboratory test (HIV and HCV)
results to recruited clients was made on request. Ethical Approval,
covering the study protocol, was obtained from Ethics Committee
of the Chinese University of Hong Kong.
Serological assays
HIV and HCV antibody tests were performed at the Liuzhou
CDC. HIV antibody status was determined by Anti-HIV 1+2
Antibody ELISA Kit (Double Antigen Sandwich). Positive samples
were confirmed by Western blot assay. The presence of HCV
antibody was determined by ELISA.
HCV RNA extraction, RT-PCR amplification, and
sequencing
HCV RNA was extracted from 200 mL of plasma by using
PureLink
TM Viral RNA/DNA Mini Kit (Invitrogen), followed by
standard protocol. cDNA was synthesized from 5 mL extracted
RNA with SuperScript III First-Strand Synthesis System (Invitro-
gen). The primers of NS5B region for nested PCR are described
elsewhere [16] with slight modification: Forward (OF) 59- TAT
GAC ACC MGY TGC TTT GAY TC-39, Outreverse (OR) 59-
TTG GAG GAG CAD GAT GTT ATS AGC TC -39,
Innerreverse (IR) 59- GAR TAC CTG GTC ATA GCC TCC
GT -39. First round PCR using primer OF and OR was conducted
with the following conditions: 95uC for 5 min, then 30 cycles of
95uC for 30 sec, 56uC for 30 sec and 72uC for 40 sec. Second
round PCR using primer OF and IR was conducted with the same
condition except that the annealing temperature is 52uC. The
forward primer OF was used to sequence the PCR product.
HCV genotyping and phylogenetic analyses
HCV genotype was determined after alignment with reference
sequences from the HCV database (available at: http://hcv.lanl.
gov/content/hcv-db/BASIC_BLAST/basic_blast.html) followed
by phylogenetic analysis. Sequences were aligned using CLUS-
TAL_X and then edited by BioEdit. Phylogenetic analysis was
performed with MEGA 3.0. The neighbor-joining method was used
with 1000 bootstrap replications (Kimura 2-parameter Substitution
Model). The reference sequences used in phylogenetic analysis were
obtained from the Genebank: D17763 (3a, Japan), X76918 (3a,
Germany), D28917 (3a, Japan), D49374 (3b, Japan), AY460204 (1b,
China-Shanghai), M84754 (1b, Taiwan), AJ238800 (1b, Germany),
NC_004102 (1a, USA), M62321 (1a, USA), D10749 (1a, Japan),
AY973866 (6a, Hong Kong), AY859526 (6a, Hong Kong), Y12083
(6a, Hong Kong), D84262 (6b, Thailand), AY878650 (6k, China-
Kunming), D84264 (6k, Vietnam), D84265 (6h, Vietnam), D63822
(6g, Indonesia), and D84263 (6d, Vietnam). The sequences of
subtype 6a in other countries or regions for phylogenetic analysis
were randomly selected from Genbank: AY834940 (China),
AY834941 (China), AY834942 (China), AY834943 (China),
AB204705 (Hong Kong), AB204706 (Hong Kong), AB204707
(Hong Kong), AB204708 (Hong Kong), D17490 (Vietnam),
D155502 (Vietnam), D155503 (Vietnam), D17475 (Taiwan),
D17474 (Taiwan), D17488 (Taiwan), L38379 (Vietnam),
DQ666268 (Taiwan), DQ663599 (Taiwan), DQ666264 (Taiwan),
DQ663598 (Taiwan), DQ663600 (Taiwan).
Statistical analysis
SPSS 13.0 was used to analyze the data. Univariate analysis was
performed with Chi-square or Fisher’s exact test for each risk
factor. Multivariate logistic regression model was used for
multivariate analysis. Factors giving a p value of less than 0.1 in
the univariate analysis were included in the logistic regression
model. A p value of less than 0.05 was considered significant.
Results
Prevalence of HIV infection, HCV infection, and
coinfection among IDUs in Liuzhou, Guangxi, Southern
China
A total of 117 IDUs were recruited from the Liuzhou
Methadone Clinic during the two-month study period. Of these
112 subjects were HCV infected as determined by the antibody
test, giving a prevalence of 96%. Among the HCV positive IDUs,
25 (21%) had HIV/HCV coinfection, while the remaining 87
were HCV monoinfection. None of the subjects was HIV positive
but HCV negative.
Demography and risk behavior pattern
Table 1 shows the demography, risk factors, and the pattern of
methadone use in HIV/HCV coinfection and HCV monoinfec-
tion. In univariate analysis, there were no significant differences
between coinfection and monoinfection in the respondents’ age,
gender, education level, smoking status, drinking status, and
previous rehabilitation history. The geographic distribution of
infections differed, with Yufeng and Chengzhong district having
more HIV/HCV coinfections, whereas HCV was evenly distrib-
uted in the 4 districts of the city. Most HIV/HCV coinfected
subjects were unemployed, while only half of the HCV mono-
infected IDUs were unemployed (76% vs. 54%, p,0.05). More
HIV and HCV in Guangxi
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x
2=6.753, p,0.01). As regards injection behaviors, there was
significantly higher prevalence of needle sharing in coinfections
(73% vs. 36%, x2=12.128, p,0.01). First injection before 1995
was also associated with coinfection. There was however no
significant difference between the two groups in condom use or
multiple sex partners. A stable daily methadone dose of over
40 mg was associated with HIV infection (64% vs. 39%, x
2=4.88,
p,0.05).
Multivariate analysis was performed by logistic regression.
Factors that gave a p value of less than 0.1 in univariate analysis
were included in the logistic regression model. These were: district
of residence, employment status, previous imprisonment, initiating
drug use before 1995, first injection before 1995, needle sharing,
and stable methadone dose .40 mg. District of residence and
needle sharing were independently associated with HIV/HCV
coinfection in the regression model (table 2).
HCV genotyping
Ninety-six of the 112 HCV infected subjects were RNA positive
(86%). Among them, 20 were HIV/HCV coinfected, and 76 were
HCV monoinfected. Overall, subtype 6a (46%) was predominant,
followed by subtype 3a (20%) and 3b (16%). Figure 1 displays the
genotype distribution by HIV status. There was no significant
difference in HCV genotype distribution between HIV/HCV
coinfection and HCV monoinfection (x
2=5.149, p=0.356).
There were more HCV genotype 3a in HCV monoinfection than
in coinfection patients (Figure 1).
Phylogenetic analysis
Figure 2 shows the phylogenetic tree of 96 sequences and
reference sequences. The sequences of coinfection IDUs were evenly
distributed in the whole tree. There is no evidence of clustering in
HIV coinfected patients. Comparing between different genotypes,
the genetic distances obtained from MEGA 3.0 within genotype 6
(0.12560.012) were shorter than those within genotype 1
(0.23760.021) and genotype 3 (0.16860.017). The 6a sequences
from Liuhzou were aligned with other 6a sequences randomly
selected from the Genebank. Overall, there’s a high degree of
sequence identity among the 6a samples in Liuzhou, than between
sequences in this study and those in neighbouring cities/countries in
Hong Kong, Tauiwan, Vietnam and China (Figure 3).
Table 1. Demographics, risk behaviors, and methadone use patterns of HIV/HCV coinfected and HCV monoinfected subjects in
the study population (n=112).
Factor
HIV/HCV coinfection
(n=25)
HCV monoinfection
(n=87) x
2 df p (Chi-square)
Demography
Birth on 1965 or after 21 70 – – 0.780
a
Male gender 17 67 0.841 1 0.359
District of residence
Liubei 2 18
Liunan 3 32 13.508 3 0.009
Yufeng 15 33
Chengzhong 5 4
Educational attainment at high school or above 5 32 2.472 1 0.116
Unemployed 19 47 3.875 1 0.049
Smoking status 24 86 – – 0.389
a
Drinking status 2 16 – – 0.354
a
Previous rehabilitation 22 72 – – 0.759
a
Previous imprisonment 19/22* 49 6.753 1 0.009
Drug abuse risk behaviors
Initiation of drug use before 1995 17 40 3.769 1 0.070
Initiation of injection before 1995 10/20* 13/67* 7.414 1 0.006
History of needle sharing 19/25 29/80 12.128 1 p,0.001
Injection in the past 1 month 9/25 24/80 0.318 1 0.573
Needle sharing in the past 1 month 3/9 6/24 – – 0.677
a
Sexual risk behaviors
Non regular partner 7 21 0.154 1 0.694
Condom use in last 3 months 3/7 13/21 – – 0.418
a
Methadone use pattern
Defaulted for #3 days in the last 1 month 22 74 – – 1.000
a
Stable methadone dose .40 mg 16 34 4.880 1 0.027
*Missing data have been excluded.
aFisher’s exact test.
doi:10.1371/journal.pone.0003608.t001
HIV and HCV in Guangxi
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In our study, almost all IDUs in Liuzhou, Guangxi, were HCV
infected. About one fifth were HIV/HCV coinfected, and which
appeared to be localized in one of the four districts (Yufeng district) of
the city. The predominant HCV genotype was 6a, the sequence of
which showed a high degree of identity, followed by 1a, 3a, and 3b,
which were circulating in smaller and relatively equal proportions.
Compared with HCV monoinfection, HIV/HCV coinfection was
associated with a higher prevalence of risk behaviours. We postulate
that both HIV and HCV infections were introduced to the IDU
population in Southern China almost simultaneously, probably in the
1990s. The specific patterns of the two infections can be explained by
the geography and history of heroin addiction in Liuzhou.
Located at the crossroad of Guangxi, Liuzhou is linking itself with
cities of Yunnan, Guizhou, Hunan, and Guangdong provinces on
one hand,and bordering Vietnamonthe other. Asa hub of the drug
trafficking route from the Golden Triangle, the problem of addiction
began to escalate in Liuzhou since the late 1980s, when HIV was
reported in IDUs in the neighbouring countries. The predominance
of genotype 6a (46%) is consistent with results in other reports on
IDUs in Southern China [4]. Some HCV genotypes have a very
restricted geographic distribution. Genotype 6 is one such example
which appears to be localised in South East Asia especially Vietnam
and Thailand. Unlike Northern China where genotype 1 (especially
1b) and 3 predominate [5,17], Southern China is characterized by
the high prevalence of genotype 6 [4,5]. There are two possible
interpretations. The first is that this is part and parcel of the rapidly
expanding epidemic of genotype 6a from South East Asia, which
then overspills into Guangxi. The second is that a longstanding
endemic of HCV type 6 in South East Asia including Southern
China has predated the HCV pandemic. The trafficking of heroin
alongside the practice of unsafe injection behaviours have resulted in
the explosive spread of genotype 6a in the local drug taking
community. The second interpretation could explain the co-
existence of a multitude of subtypes of genotype 6 characterized
by extensive sequence variability [7,18], which have probably
resulted from a long evolutionary process over time. A similar
endemic spread seems to have occurred in the Indian subcontinent
with genotype 3, in Western Africa with genotype 2, and in Egypt
with genotype4 [19,20,21].In contrast, therelatively low proportion
of other HCV genotypes may reflect their introduction in Southern
China from other areas, possibly Northern China, Japan or Europe.
The identity of the 6a sequences in Liuzhou suggested that the virus
was introduced almost simultaneously over a short period of time in
the IDU population.
The relatively lower HIV prevalence in the same IDU
population needs to be accounted for. Biologically, HIV
Table 2. Multivariate logistic regression analysis for risk factors associated with HIV/HCV coinfection.
BS E P value Odds ratio 95% CI
Residential district of Chengzhong 2.973 1.392 0.033 19.550 1.277–299.314
Needle sharing 2.164 0.753 0.004 8.708 1.989–38.116
doi:10.1371/journal.pone.0003608.t002
Figure 1. HCV genotypes, by HIV status, among 96 drug users in Liuzhou cohort.
doi:10.1371/journal.pone.0003608.g001
HIV and HCV in Guangxi
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the most important reason why the prevalence of HIV in Liuzhou
was only one-fifth that of HCV infection. The localization of
HIV/HCV coinfection in some but not all of the districts in
Liuzhou suggested that transmission has been less efficient and
more strongly associated with risk-taking behaviours, as illustrated
in our findings. Interestingly, previous imprisonment was also
found to be associated with HIV/HCV coinfection. Imprisonment
Figure 2. HCV NS5B phylogenetic tree for drug users in
Liuzhou, Guangxi, Southern China, with 96 drug users of
which 20 are HIV/HCV co-infected (underlined).
doi:10.1371/journal.pone.0003608.g002
Figure 3. HCV genotype 6a in the study population (n=34) and
other countries and regions. Codes for sources of samples:
CN=China; TW=Taiwan; HK=Hong Kong VN=Vietnam.
doi:10.1371/journal.pone.0003608.g003
HIV and HCV in Guangxi
PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3608may simply be a surrogate of a higher demand for heroin, and
therefore a marker for higher prevalence of risky behaviours.
Outbreak of HIV infection in prison resulting from needle sharing
is another possibility though this cannot be proven in our study.
We also tested the association between HIV infection and the
timing for initiating drug injection. IDUs who started heroin use or
initiated injection before 1995 were more likely to have contracted
HIV infection. The year 1995 was chosen as the cutoff because it
was the same year that the national government began to crack
down on heroin addiction as a means to control HIV spread. This
was theoretically also the same timepoint that the association
between HIV transmission and injection drug use was officially
acknowledged. The results may mean that IDUs after 1995 were
more aware of the risk of HIV and could have reduced the level of
risk, which is in line with a health belief model. Alternatively, this
may also be a reflection of the phenomenon that longer duration
(thus before 1995) of addiction was associated with enhanced risk
of exposure. From a molecular perspective, the HCV sequences of
coinfection group did not reveal any clustering, suggesting that
HIV could have been introduced at the same time with HCV in
Liuzhou after 1990s.
Knowingly our research carries some limitations especially that
on sampling. Our subjects were recruited exclusively from the
city’s first methadone clinic. It may be argued that methadone
clients were highly selected, and that their profile of risk
behaviours, and their geographic distribution may have been
biased. It’s possible that IDUs who are still actively injecting
heroin could be missed, thus underestimating the risk levels in the
analysis. On the other hand, heroin users who have been injecting
drugs for a long period of time were preferentially recruited by
methadone clinics, so older IDUs could have been over-
represented. As a hard-to-reach population, there is no perfect
sampling frame for IDUs in China. The HCV and HIV results are
robust enough to reflect the situation in a significant proportion of
IDUs in Southern China. Another limitation is that the analysis
was based on results on self-reported behaviours. Though the
questionnaires were administered by trained research staff,
reliability of such results would be difficult to be ensured.
Extrapolation of results in this study to the entire IDUs
populations in Southern China should be considered with care.
In conclusion, our study suggested a short history of the
introduction of both HIV and HCV infections to IDUs in
Liuzhou, Southern China. This is different from Northern China
where HCV genotype 1b predominated largely because of the use
of contaminated blood products before 1990s. This was followed
by HIV spread through the same transmission route [5]. As
exemplified in our study in Liuzhou, HCV and HIV infections
took root in Southern China after 1990s through needle sharing in
IDUs. In the neighbouring city of Hong Kong, the situation was
different despite its similar location in Southern China. Charac-
teristically, methadone clinics were established in Hong Kong in
the 1970s, long before HIV spread in any IDU population in the
world was reported. Todate HCV infection had affected a
majority of the IDUs in Hong Kong but HIV/HCV coinfection
was distinctly uncommon. [22]. Interestingly Genotype 6a is also
common in Hong Kong, which may again reflect the transmission
of an endemic strain before the HIV pandemic. In other countries
of South East Asia, such as Thailand, Myanmar in the Golden
Triangle HCV might have spread first through the drug trafficking
routes that have been in existence for decades. The spread of HIV
took place more recently only when the virus landed on the IDUs,
as manifested in the epidemiologic pattern of Thailand [23]. The
extremely high HCV prevalence (96%) in IDUs in Liuzhou is a
cause for concern. There is the risk that the virus may spread from
IDUs to the general public, and then propagated through
unprotected sex alongside needle-sharing. The high HIV preva-
lence in IDU also means that with time, a significant number of
IDUs would develop complications arising from chronic HCV
infection. Prevention, diagnosis and treatment of HIV/HCV co-
infection would become another clinical cum public health
challenge in Guangxi, Southern China.
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